A detailed history of Pdt Partners, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 143,390 shares of SAGE stock, worth $1.56 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
143,390
Previous 148,796 3.63%
Holding current value
$1.56 Million
Previous $3.22 Million 16.66%
% of portfolio
0.27%
Previous 0.37%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$18.62 - $26.95 $100,659 - $145,691
-5,406 Reduced 3.63%
143,390 $2.69 Million
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $561,375 - $730,773
-32,829 Reduced 18.08%
148,796 $3.22 Million
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $2.36 Million - $6.91 Million
141,094 Added 348.11%
181,625 $3.74 Million
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $577,677 - $846,122
14,211 Added 53.99%
40,531 $1.91 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $46.57 $615,290 - $768,824
16,509 Added 168.27%
26,320 $1.1 Million
Q4 2022

Feb 14, 2023

BUY
$32.2 - $43.61 $4,894 - $6,628
152 Added 1.57%
9,811 $374,000
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $2.44 Million - $3.27 Million
-75,502 Reduced 88.66%
9,659 $378,000
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $810,601 - $1.12 Million
-29,455 Reduced 25.7%
85,161 $2.75 Million
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $1.13 Million - $1.69 Million
36,933 Added 47.54%
114,616 $3.79 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $415,702 - $528,432
-11,217 Reduced 12.62%
77,683 $3.31 Million
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $133,220 - $189,837
-3,309 Reduced 3.59%
88,900 $3.94 Million
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $2.56 Million - $3.7 Million
46,706 Added 102.64%
92,209 $5.24 Million
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $1.93 Million - $2.64 Million
-27,297 Reduced 37.5%
45,503 $3.41 Million
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $337,025 - $513,876
-5,770 Reduced 7.34%
72,800 $6.3 Million
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $1.24 Million - $1.88 Million
-30,105 Reduced 27.7%
78,570 $4.8 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $2.82 Million - $4.69 Million
108,675 New
108,675 $4.52 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $645M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.